Breckenridge Pharmaceutical Enters Strategic Collaboration with Medichem
Friday, February 06, 2026
Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International, has entered into a strategic collaboration with Medichem Solutions S.L., a subsidiary of Medichem. The agreement covers a range of injectable medicines used in areas such as anaesthesia, critical care, and emergency medicine.
The collaboration is expected to expand Breckenridge’s injectable medicines portfolio and strengthen its presence in the U.S. hospital market. It also supports the company’s long-term focus on supplying high-quality and affordable medicines that clinicians rely on in hospital settings. Both companies share a commitment to quality, reliability, and meeting essential patient needs.
As part of its broader strategy, Breckenridge continues to develop three patient-focused business areas: specialty, hospital, and retail. The partnership with Medichem Solutions supports this approach by adding new injectable products and helping to build a more diversified portfolio for healthcare providers.
For Medichem Solutions, the collaboration includes manufacturing some of the products at its new sterile fill-and-finish facility in Asturias, Spain. The site enhances Medichem’s business-to-business capabilities and supports its aim of helping partners expand access to affordable, high-quality medicines.
Breckenridge’s growing hospital portfolio complements its wider focus on complex and underserved patient groups, including oncology, autoimmune conditions, rare diseases, and paediatric care. Through strategic collaborations such as this, the company aims to provide practical treatment options that support patients throughout their care pathway.
Source: prnewswire.com
